MX2024004849A - Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos. - Google Patents

Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos.

Info

Publication number
MX2024004849A
MX2024004849A MX2024004849A MX2024004849A MX2024004849A MX 2024004849 A MX2024004849 A MX 2024004849A MX 2024004849 A MX2024004849 A MX 2024004849A MX 2024004849 A MX2024004849 A MX 2024004849A MX 2024004849 A MX2024004849 A MX 2024004849A
Authority
MX
Mexico
Prior art keywords
antibodies
factor
clot formation
domain
methods
Prior art date
Application number
MX2024004849A
Other languages
English (en)
Spanish (es)
Inventor
Dan Chalothorn
Lori Morton
Kehdih Lai
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024004849A publication Critical patent/MX2024004849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024004849A 2021-10-22 2022-10-21 Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos. MX2024004849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163270629P 2021-10-22 2021-10-22
PCT/US2022/078530 WO2023070097A2 (en) 2021-10-22 2022-10-21 Factor xi a2 domain-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024004849A true MX2024004849A (es) 2024-05-06

Family

ID=84360943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004849A MX2024004849A (es) 2021-10-22 2022-10-21 Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos.

Country Status (12)

Country Link
US (1) US12304969B2 (https=)
EP (1) EP4419142A2 (https=)
JP (1) JP2024539157A (https=)
KR (1) KR20240099304A (https=)
CN (1) CN118414168A (https=)
AU (1) AU2022368930A1 (https=)
CA (1) CA3235457A1 (https=)
CL (1) CL2024001237A1 (https=)
CO (1) CO2024006258A2 (https=)
IL (1) IL312308A (https=)
MX (1) MX2024004849A (https=)
WO (1) WO2023070097A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
TWI736575B (zh) * 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
CA3125303A1 (en) 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof

Also Published As

Publication number Publication date
EP4419142A2 (en) 2024-08-28
CN118414168A (zh) 2024-07-30
KR20240099304A (ko) 2024-06-28
CL2024001237A1 (es) 2024-09-13
WO2023070097A2 (en) 2023-04-27
AU2022368930A1 (en) 2024-05-02
US12304969B2 (en) 2025-05-20
US20230131338A1 (en) 2023-04-27
IL312308A (en) 2024-06-01
CA3235457A1 (en) 2023-04-27
WO2023070097A3 (en) 2023-06-08
CO2024006258A2 (es) 2024-06-27
JP2024539157A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
Stupacher et al. Musical groove modulates motor cortex excitability: A TMS investigation
Pastore et al. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors
Senerchia et al. Trends in incidence of primary cutaneous malignancies in children, adolescents, and young adults: a population‐based study
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
Tisato et al. Inhibitory Effect of Natural Anti‐Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient‐Derived Endothelial Cells
Louis et al. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Zollner et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
EP2547355A4 (en) TFPI HEMMER AND USE METHOD THEREFOR
Dzik Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal
GEP20267851B (en) Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
BR112014022435A2 (pt) inibidores de tfpi e métodos de uso
George et al. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen‐like FXaI16L
Curto et al. Implications of apixaban for dental treatments
MX2024004849A (es) Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos.
MX2025005261A (es) Anticuerpos de union al dominio catalitico del factor xi y metodos de uso de estos
WO2020023094A3 (en) Treatment of lysosomal storage disorders
Altorjay et al. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal
Smith Angiotensin and systems thinking: wrapping your mind around the big picture
Nwaehujor Chinaka et al. Anticoagulant and antioxidant activities of Dracaena arborea Leaves (Wild.) Link
Bhat et al. Synergistic effect in bleed reduction by superfva and recombinant human FVIIa in vivo suggests a novel bypassing strategy for hemophilia patients with inhibitors
Zhu et al. Pinocembrin shows antithrombotic activity on the thrombosis-induced experimental rats.
Gupta et al. + Ophitoxaemia and myocardial infarction—the issues during primary angioplasty: a review
Hermanowicz et al. Aliskiren inhibits experimental venous thrombosis in two-kidney one-clip hypertensive rats